idc btig estim compani document
million except per share amount
exparel potenti benefactor opioid crisi initi coverag
buy rate price target
initi coverag share buy rate
pt one co focus pain manag space
achiev profit post approv commerci lead drug
exparel share under-perform year believ
revenu ebitda growth could acceler next month exparel
util increas nerv block ambulatori surgic care set
estim exparel sale current annual run rate
util spread across number surgic procedur orthoped
abdomin women health estim total
revenu ep
believ exparel liposom bupivacain inject post oper pain
like benefit number macro factor includ movement away
widespread prescrib opioid hospit ambulatori
surgic care set due opioid epidem addit brachial
plexu nerv block indic approv april receiv medicar
reimburs begin earli discuss number kol
post pain manag forum last month suggest exparel volum growth
could benefit era protocol hospit focu improv patient
outcom lower prescrib opioid reduc overal cost
believ enter new growth phase exparel driven focu
use high valu surgic procedur averag cost per procedur
mani case use exparel tie physician prefer
experi mani physician hospit current use exparel
due higher cost vs gener bupivacain overal penetr rate
exparel across surgic procedur remain singl digit think
rate could rise releas addit clinic data pediatr c-section
studi expect also would note exparel sale trend risen
possibl result exparel gain medicar reimburs
think higher volum trend like continu
potenti competit new entrant risk believ
like new entrant focu could heron rate
fda approv decis could occur late march
valuat initi coverag buy rate pt base
multipl ebitda estim discount back
rate share buy pt base multipl ebitda estim
discount back believ top line growth next year achiev manag
continu focu expand treatment indic exparel brachial plexu nerv block
obtain reimburs challeng remain potenti competit heron
see pcrx exparel benefit expand use conjunct upper lower extrem surgeri near
term expect addit studi read pediatr c-section indic
top-lin data pediatr studi
top-lin data c-section block choic studi
potenti snda file pediatr set
estim exparel sale grow steadili sale estim
respect
believ gross profit margin could expand time co increas
manufactur capac swindon uk estim gross profit margin
increas
exparel sale growth surpass estim base higher-than-expect
util high valu surgic procedur
higher-than-expect ebitda ep result margin expans
iovera garner stronger interest conjunct exparel orthoped
exparel sale come forecast due weaker-than-expect data
inc oper
hold compani engag
develop
commerci
manufactur pharmaceut
product use postsurg
outcom acut care
practition patient
redefin pain manag
surgeri opioid-fre
altern indic single-dos
infiltr surgic site
compani found decemb
headquart
co abl scale manufactur improv gross margin
addit competitor enter market grab share exparel
launch coverag share buy rate pt arriv via dcf analysi
believ enter new growth phase exparel driven focu use high valu surgic procedur
averag cost per procedur mani case use exparel tie physician prefer
experi mani physician hospit current use exparel due higher cost vs gener bupivacain
overal penetr rate exparel across surgic procedur remain singl digit think rate
could rise releas addit clinic data pediatr c-section studi expect also would note
exparel sale trend risen possibl result exparel gain medicar reimburs
think higher volum trend like continu
pacira bioscienc found parsippani nj engag develop manufactur
commerci non-opioid solut post-surg pain manag pacira primari product exparel
approv octob indic administr surgic site produc postsurg analgesia
date exparel fda-approv long-act non-opioid analges sinc approv pacira initi complet
sever clinic trial exparel variou indic within postsurg realm see pacira one lead
co pain manag space uniqu posit growth time tradit opioid treatment
signific scrutini
believ share could benefit exparel sale growth head
believ exparel liposom bupivacain inject post oper pain like benefit number macro
factor includ movement away widespread prescrib opioid hospit ambulatori surgic care
set due opioid epidem addit brachial plexu nerv block indic approv april
receiv medicar reimburs begin earli discuss number kol post pain manag
forum last month suggest exparel volum growth could continu benefit era protocol hospit
begin implement focu improv patient outcom lower usag opioid reduc overal cost
potenti competit new entrant risk believ like new entrant focu could
heron refil nda follow receipt complet respons letter would also note fda recent
request fda advisori panel meet held januari durect drrx rate posidur depot
bupivacain addit trevena trvn rate plan resubmit nda oliceridin protein-bias ligand
-opioid receptor follow complet qt prolong studi
share ytd under-perform nbi biotech index
estim exparel sale estim vs consensusconsensusbtig gross profit ebitda projectionsgross profitebitda
near-term catalyst top-lin readout pediatr c-section studi year end
year end expect releas top-lin data two clinic studi phase studi evalu
pharmacokinet safeti exparel postsurg analgesia pediatr patient age year less year
age phase choic studi evalu efficaci safeti exparel dose via infiltr
transversu abdomini plane vs standard care patient undergo elect cesarean section anoth key item
earli fda approv decis heron end march think could potenti
competitior exparel approv
exparel non-opioid analges initi approv brachial plexu nerv block indic
ad
exparel initi approv octob administr surgic site via wound infiltration/field block
clinic develop program includ clinic studi observ studi follow initi approv pacira
conduct three addit nerv block studi snda nerv block submit may fda issu
feb basi efficaci pk safeti data addit studi perform snda
resubmit exparel approv nerv block april time sept co receiv warn
letter fda regard promot drug unapprov use overst effect follow
legal battl fda amic resolut achiev allow market exparel
field block gener limit hemorrhoidectomi bunionectomi
approxim million surgeri perform annual us
total address market exparel surgeri local anesthet requir standard bupivacain
cost current use surgeri annual last hour acut pain result clinic physiolog
chang increas morbid mortal diminish qualiti life extend length stay therebi increas hospit
expenditur reduc patient satisfact cathet pump system offer longer-act pain relief
sever well-docu limit continu peripher nerv block requir placement perineur cathet
local anesthet reservoir/pump infus manag cathet site care risk bacteri colon
infect pump failur cathet migrat issu patient complianc placement cathet also technic
challeng requir consider time
treatment indic top-lin data block top line file pediatr treatment indicationmar potenti fda approv decis clinic data readoutupcom catalyst
nerv block indic expans allow procedur amen nerv block field block/infiltr
remov risk associ cathet
clinic trial plan complet
expect timet releas addit clinic studi exparel
current run phase trial c-section field block pediatr infiltr co plan initi
anoth phase trial nerv block lower extrem surgeri nerv block current approv exparel
believ one pcrx largest custom depart defens co also identifi ambulatori surgic
center primari growth area due high throughput natur surgeri perform oct aetna
offer expand coverag exparel certain ambulatori center rate addit reimburs
exparel also activ medicare/medicaid repres larg volum patient import
commerci payor reli set reimburs rate c-code
restoremulticent random active-control studi evalu efficaci safeti exparel administ via fascia iliaca compart block versu fascia iliaca compart block continu infus local anesthet per standard care cathet intertrochanter hip phase random active-control studi evalu efficaci safeti exparel administ via infiltr transversu abdomini plane versu standard care subject undergo elect cesarean sectionfusionmulticent prospect active-control real world studi exparel multimod regiment compar standard care postsurg pain manag insubject undergo lumbar posterior spine surgeriesstridemulticent studi evalu pharmacokinet safeti exparel postsurg analgesia pediatr subject age less yearsrandom double-blind active-control multicent studi evalu efficaci safeti pharmacokinet exparel vs bupivacain administ combin sciatic femor triangl nerv block postsurg analgesia subject undergo lower extrem surgeri playsourc co report btig
penetr ambulatori surgeri center growth opportun
ambulatori surgeri center asc health care facil focus provid same-day surgic care outpati
includ diagnost prevent procedur comparison tradit in-pati surgeri hospit asc focu
high-qual cost-effect altern surgeri physician abl assembl special train highli skill
staff allow high-throughput natur center histor trend move surgeri
outpati set transit slow medicar gener reimburs amount paid
hospit outpati servic servic sourc associaton org becker report
medicare-certifi asc estim patient undergo surgeri treat
outpati basi patient expect treat ambulatori environ
given nearli full reimburs ambulatori set believ signific market opportun
lie also forecast base compani file surgeri trend surgeri perform outpati
set today believ trend like due increas impetu provid
similar greater level coverag outpati set
associ center medicar medicaid servic june
overview clinic studi
co perform three pivot trial bunionectomi hemorrhoidectomi one trial compar liposom bupivacain
activ control standard bupivacain studi addit one health econom outcom studi summar
total clinic studi observ studi perform pacira submit snda expand
indic nerv block may fda issu februari pacira design two addit phase
nerv block re-fil oct fda approv april addit trial brachial plexu nerv
block seen appendix
exparel receiv medicar reimburs asp begin
exparel bupivacain liposom inject suspens inject local analges approv infiltr field block
interscalen brachial plexu nerv block postsurg set avail mg ml dose
mg ml dose ml dose use brachial plexu nerv block certain
type infiltr wherea ml dose use bulk set
exparel receiv c-code effect jan provid payment exparel averag sale
price asp set nation medicar reimburs rate exparel administ ambulatori surgic center
asc discuss co believ exparel reimburs necessarili drive
larg volum patient import catalyst commerci payor reli c-code set
studi phaseblock type surgeri typeexparel dose controlopioid rescu medic useopioid-fre subjectsphas mg reduct geometr ls mean ratio hour vs opioid free hour mg reduct mean number percocet tablet use hour vs opioid free hour mg ir bupivacain reducion geometr ls mean ratio hour vs opioid free hour mg ir bupivacain reduct ls mean hour vs opioid free hour nerv block mg reduct geometr ls mean ratio hour vs opioid free hour key opioid relat endpoint result local analgesia studiesplacebo control local analgesia studiesact control region analgesia studiessummari key opioid relat endpoint result region analgesia studi
pacira target high valu orthoped indic via partnership depuy
co activ target orthoped indic avenu penetr convers manag
suggest split orthoped soft tissu infiltr believ make sens given
averag cost total knee arthroplasti increment cost exparel less signific particularli given
better outcom data present orthoped situat note depuy synth orthoped divis johnson
johnson rate market leader orthoped
world-wide orthoped sale chart repres breakdown
sale segment knee hip make respect exparel target major
market analysi suggest exparel see usag across wide varieti surgic
estim revenu current come orthoped procedur expect segment grow
addit revenu abdomin women health dental plastic procedur
sale segment kneehipextremityspinetraumesport breakdownorthopedicsoft tissu abdomin women cardiothorac plastic dental
target exparel use high valu surgic procedur could lead growth
beyond
believ exparel use conjunct major surgic procedur perform oper room
hospit accord ahrq agenc healthcar research qualiti total knee replac
procedur perform us procedur tabl on-label exparel
except lower extrem nerv block co current conduct phase studi evalu lower extrem
nerv block indic knee hip arthroplasti take number spot respect common oper
room procedur spinal fusion co current initi phase clinic trial fifth common
procedur hysterectomi abdomin surgeri relat women health anoth area interest pacira
healthcar cost util project agenc healthcar research qualiti btig estim
stay procedurer per populationcost per coronari angioplasti excis intervertebr replac total common duct excis abdomin lysi periton fractur disloc hip unilater arteri bypass graft fractur disloc lower extrem hip room procedur perform frequent hospit stay
pacira multipl clinic outcom studi exparel
econom data reveal import cost save beyond direct cost product pacira spent
signific time evalu outcom use exparel rel standard care given exparel need pass
committe individu hospit believ data import support decis
tabl show studi pacira run exparel variou type surgic procedur orthoped
studymethodsclin outcomeeconom outcometot hip outpati tha case requir transfer hospit averag surgic time minut total lo hrstotal joint patient undergo total joint arthroplasti tha tka discharg rate home patient readmiss postsurg minut average recoveri time hip procedur minut knee procedurestot joint arthroplasti tja patient report pain level expect well control patient discharg hometot knee patient receiv tkasignificantli better pain control hr reduct opioid use patient free opioid hourstot shoulder arthroplasti rotat cuff reduct opioid use hour patient opioid free compar placebo hoursshould patient undergo sasignificantli less pain pod reduct losminim invas tlif mi adult patient treat enhanc recoveri discharg reduct total cost acute-car hospit day shorter losunilater single-level adult patient undergo tlifsignificantli better pain control report first lower mean total per-pati cost day shorter losimplant-bas breast reconstruct patient undergo lower opioid consumpt lower antiemet utliz hour shorter lo lower hospit chargesimplant-bas breast reconstruct patient undero mastectomysignificantlli better pain day shorter lo patient discharg dayabdomin base microsurg patient undergo breast reconstructionfew total opioid day shorter losmicrovascular breast adult patient undergo microvascular breast fewer total opioid use day shorter lo postsurgerygynecolog oncolog robotic-assist patient undergo robotic-assist hysterectomysignificantli less pain first hour hour shorter losabdominallaparoscop colorect patientsutil fewer day shorter lo incur lower overal cost hospitalorthoped spinewomen healthclin outcom studi summari
post-operative pain current treatment
acut post-operative pain experienc patient follow surgic procedur less half
patient report adequ post oper pain relief believ physician hospit continu challeng
prescrib patient pain post-operative pain often manag multipl pain-reduc analges
system pharmacolog therapi rang opioid counter nonsteroid anti-inflammatori drug nsaid
acetaminophen howev side effect includ hepatotox acetaminophen gi bleed ulcer nsaid
limit prolong usag move away opioid intraven ketamin usag increas howev
contraind certain patient larg extent opioid main line treatment patient experienc
post oper pain howev given potenti addict depend mani physician hospit begun
move away wide prescrib medic
opioid crisi lead hospit physician move non-opioid base treatment
almost peopl die overdos involv opioid includ prescript illicit
opioid postsurg opioid use link subsequ persist opioid use recent larg studi claim data found
approxim opioid-nav patient underw surgeri receiv opioid continu use opioid
day surgeri extrapol popul translat approxim million patient year
addit incid persist opioid use differ among patient undero minor major
surgeri suggest mani patient like continu opioid therapi reason intens pain
physician move taper prescrib opioid due addict risk potenti higher cost
given on-going opioid epidem physician feel increas pressur limit opioid prescript case
obtain pain reliev friend rel opioid abus obtain prescript doctor studi
publish jama brummet et al found patient undergo total hip replac undergo
knee arthroplasti take opioid surgeri continu use opioid month surgeri furthermor
incid new persist opioid use surgic procedur among surgeon prescrib
opioid admit feel pressur prescrib opioid patient actual requir due hcahp
formulari option patient request given increas awar regard risk surround opioid use open
market new treatment exparel mitig need excess opioid prescript
samhsa substanc use mental health indic us
shown peopl misus opioid receiv opioid prescript doctor minim
opioid prescript hospit downstream abus could significantli avoid
financi forecast market model
estim revenu dilut ep per share
respect base forecast reflect steadi ramp exparel sale increas gross margin
current project increas
gross margin histor trend upward exparel gm current exparel
produc batch san diego ca plant expans uk develop batch
believ signific catalyst gross margin improv earli plant expans done
via partnership pantheon thermo fischer co buy pt cover analyst sung ji nam
increment contribut ep per year estim
estim expens increas annual reach
co current run multipl phase clinic trial plan initi studi lower extrem nerv
forecast sg margin rang sg cost estim
respect sign market agreement depuy synth compani johnson
 johnson divis involv market exparel specif orthoped spine space pay high-
single-digit commiss annual revenu depuy part arrang cost includ sg
current estim ebitda margin think could increas next year gross margin
increas sg cost stay total sale estim exparel grow compound-annual-growth-rate
given one cash flow posit co non-opioid pain manag space believ
signific de-risk factor co alreadi profit gener posit free cash flow estim
increas dont expect co need rais addit fund near term estim
cash balanc sheet
upcom estim total revenu adj ep higher bloomberg
consensu estim exparel sale iovera sale
btig estim figur except ep
exparel market model suggest penetr rate infiltr nerv block like increas
market model base penetr rate infiltr nerv block indic current believ
exparel sale attribut use infiltr repres overal market penetr rate nerv
block repres revenu penetr current expect penetr
increas due receipt c-code earli growth rate penetr standard infiltr
administr modest peak reach
exparel sale project suggest sale could surpass
market model compound-annual-growth-rate surgeri requir post-op pain rate surgeri use surgeri use patient per dose yoy growth total surgeri use nerv surgeri use nerv patient per dose nerv yoy growth total btig research compani present filingstot sale yoy exparel yoy changesal mm exparel salesexparel salesexparel sales-btig estim
financi metric believ profit could increas steadi exparel
tabl show steadi growth pcrx key financi metric figur consensu gross
profit also show forecacst grow sg expens well ep gross profit forecast
consensu project co need continu increas sg spend market exparel current
estim sale peopl cost also rise current level
capit structur analysi suggest financi capac addit busi
pacira finish cash major debt oblig convert debt believ
co financi capac addit busi develop deal march co issu
convert senior note due april holder may convert note prior octob sale price
greater convers price initi convers price per share compani common stock
june note trade premium par
pacira inc estim capit structur grossnet forecast equival oper expensescash equival capit debt convert due octob financ carri valu convert long-term debt short-term share outstand market enterpris valu convert debt outstand due common share per face share convert debt co report btig estim factset share price
valuat think compar medic devic co
current share trade adj ebitda estim
compar highlight tabl includ medic devic co orthoped co
pharmaceut co base view exparel sale like grow steadili think pcrx
comp may skew medic devic co exparel alreadi fda approv product establish
grow network prescrib think less risk also think exparel util could increas time
addit clinic studi readout occur tabl valuat metric
estim consensu averag except btig estim
nametickerpriceytd returnshar market valu yr ep pegcash debt valu management liposom scienc tech abiom technolog ent medic medic hold cap pharma/m tech johnson surgic life biomet hold compani rangeev/revsev/ebitdaep
discount analysi suggest share worth
rate share buy pt base multipl ebitda estim discount
back believ top-lin growth next year achiev manag continu focu
expand treatment indic exparel brachial plexu nerv block obtain reimburs
dcf model horizon year discount termin termin non-convert dilut per co report btig estim
exparel patent protect end seem around corner howev fda draft
guidanc suggest signific challeng exist potenti gener filer
exparel last orang book list patent exparel manufactur via batch process expir
decemb believ hurdl gener co copi exparel high given fda requir
demonstr bioequival back februari fda issu draft guidanc see appendix detail
requir would need met gener manufactur includ need run pharmacokinet pk
bioequival studi use test product produc commerci scale manufactur site
base channel check believ could take least five year gener co develop equival
version vivo/in vitro studi would requir proof equival drug composit well liposom characterist
gener exparel would demonstr activ ingredi bupivacain also mvl
depofoam due complex liposome-bas parenter drug time anda competitor would need
commerci scale manufactur process vivo vitro studi demonstr bioequival
us patent trademark offic btig research
descriptionpat file datemultivescular liposom control releas encapsul biolog activ util neutral lipid modifi vivo releas multivesicular liposom control releas encapsul biolog activ liposom anesthet inform
exparel bupivacain liposom inject solut consist microscop liposom depofoam drug deliveri system
form honeycomb-lik structur numer non-concentr intern aqueou chamber contain bupivacain
chamber separ adjac chamber lipid membran bupivacain amide-typ local anesthet activ
ingredi releas depofoam particl reorgan barrier lipid membran subsequ
diffus drug time
exparel approv oct base result two phase placebo-control clinic trial one patient
undergo bunionectomi one patient undergo hemorrhoidectomi
liposom microscop structur consist phospholipid bilay encapsul aqueou core aqueou
chamber contain bupivacain releas extern lipid layer break bupivacain local amid
anesthet act inactiv voltage-depend sodium channel releas bupivacain bind
site slow durat action longer lidocain
scan electron microscop imag
cross-sect diagram depofoam
due multi-vesicular liposom structur pk profil exparel significantli differ standard bupivacain
liposom structur break bupivacain releas lead second peak plasma concentr hour
pacira brief inform anesthet analges drug product advisori committe
bupivacain relat amide-typ local anesthet chemic relat lidocain bupivacain block
gener conduct nerv impuls increas threshold electr excit nerv slow
propag nerv impuls reduc rate rise action potenti import interest mix
opinion regard cardiotox bupivacain vivo studi demonstr neg inotrop agent caus
decreas blood pressur heart rate alter electr excit heart dilat blood
vessel observ via widen qr complex lengthen pr interv howev exparel
safeti profil well character use estim million patient exposur
structur formula bupivacain
exparel administ via three differ mechan infiltr field block nerv block
infiltr anesthet appli directli surgic site prior sutur
field block drug infiltr around border surgic site leav oper
nerv block anesthet appli directli adjac nerv suppli surgic
set brachial plexu nerv block use surgeri shoulder arm hand
exparel current approv infiltr field block interscalen plexu nerv block kol call confirm
administr nerv block gener discret anesthesiologist/surgeon result longer
profound pain relief also associ motor block patient undergo orthoped surgeri exampl
knee surgeri nerv block would prefer orthoped surgeon want patient ambul earli
possibl follow surgeri best recoveri
brachial plexu nerv block upper extrem surgeri
benefit analysi exparel tka reveal save per patient
cost benefit analysi exparel publish american journal health-system pharmaci evalu
overal cost hospit vs standard bupivacain studi compar singl administr exparel plu
epinephrin relat ketorolac bupivacain plu hydrocodon analysi conduct total direct hospit
cost subcategori hospit cost net hospit cost total direct hospit cost minu intervent cost
liposom bupivacain cost perspect exparel associ slightli lower adjust mean total direct
hospit cost compar total cost control group
studi also report mean pain score similar level mean amount post-operative opioid use
day follow surgeri signific lower exparel group vs control group significantli larger group patient
abl ambul day surgeri exparel group versu control group could walk twice
distanc control group patient exparel group discharg hospit within day
surgeri compar patient control group mean significantli shorter liposom
bupivacain group control group
studi includ adjust model standard age sex race score physic statu classif
score cost similar across cost categori except mean cost room board
significantli lower exparel group explain fact patient undergo exparel treatment gener
shorter length stay therefor less room board cost incur adjust model cost
lower per patient exparel benefit cost ratio benefit per patient realiz everi
invest exparel
direct hospit exparel control laboratori per patient exparel group group hydrocodon ketorolac/bupivacaineadjust pmedic surgic suppliescategorypt physic therapi ot occup therapycalcul via student test logarithm transformationderiv gener linear model gamma distribut log link adjust patient age sex race bodi mass indexsourc -benefit evalu liposom bupivacain manag patient undergo total knee arthroplasti kirk et al
iovera potenti product
march pacira acquir myoscienc way develop pcrx non-opioid product portfolio specif
orthoped busi deal structur up-front commerci regulatori mileston
payment myoscienc develop iovera system freez peripher nerv cryoneurolysi deliv
immedi pain relief believ iovera potenti anoth contributor top-lin growth revenu
expect benefit ep begin base estim
given increas focu orthoped busi iovera intend use total knee arthroplasti acl tear
prior surgeri also use temporari pain relief day nerv regener time effect
felt immedi co exist code exparel iovera conjunct total knee arthroplasti
patient iovera market via razor-blad model replac smart tip price
co intend capac suppli smart tip end given pain reduc opioid-spar
effect believ iovera meaning contributor top-lin conjunct exparel last friday center
medicar servic publish final rule includ favor increas hospit outpati depart
hopd payment iovera start believ iovera reimburs hopd set
exparel gain fda approv late spent last six year run studi support
product util wide number high valu surgic set howev reimburs hospit set remain
challeng result believ co focu new brachial plexu nerv block indic may allevi
pressur reimburs
potenti gener research co drug deliveri technolog suggest may difficult
competitor develop ab-rat formul given fda requir competitor would need
commerci scale manufactur process well vivo vitro studi demonstr bioequival
would requir clinic studi run
pacira continu focu grow exparel challeng reimburs environ mani hospit focus
cost cut howev opioid crisi physician hospit look taper opioid post surgic patient
believ exparel use could expand one non-opioid base treatment avail
competit landscap fda approv new pain medicin challeng number co
productreject reasondateheron bupivacain meloxicamne addit non-clin inform base complet review nda fda identifi clinic safeti efficaci issu requir clinic studi data analysesapril drrx posimir bupivacain ernda contain suffici inform demonstr posidur safe use manner describ propos label submit june includ multipl trial address issu rais fda pdufa expect dec -rtf bupivacain er collage-matrix implant xaracol character drug/devic combin would requir compani submit addit inform dec pharma meloxicam long-act nsaid preferenti inhibit although outcom pivot phase ii trial demonstr statist signific outcom primari endpoint state data ad hoc analys select secondari endpoint suggest analges effect meet expect fda delay onset fail meet prescrib expect intraven iv drug also cite regulatori concern role iv meloxicam monotherapi acut pain well would meet patient prescrib need set march may trvn oliceridin g-protein bias mu-opioid receptor ligandfda request addit clinic data qt prolong indic submit safeti databas adequ size propos dose fda also request certain addit nonclin data valid report nov pain manag drug candid
season manag helm
david stack pacira year founder network inc inc david
businessperson head differ compani present occupi posit chairman chief
execut oper offic inc chairman inc presid manag
inc david stack also board compani past career occupi
posit presid chief execut offic director medicin co presid gener manag innovex inc
manag director mpm capit llc director-busi develop infecti diseas central florida pa vice
president-busi develop market inc director endeavor pharmaceut inc director
qrxpharma ltd unit state director-busi develop plan roch laboratori inc princip pt
tran corpora david stack receiv undergradu degre siena colleg undergradu degre
albani colleg pharmaci
reinhardt join pacira june current occupi posit presid inc
vice president-market depuy synth sale inc mr reinhardt receiv graduat degre univers hull
kristen william pacira year current kristen secretari chief administr offic pacira
bioscienc inc past ms held posit corpor associ paul hast janofski walker llp
vice president-corpor complianc bioenvis inc ms receiv undergradu degre bucknel
univers graduat degre univers denver
charl laranjeira pacira year charl occupi posit chief technolog offic pacira
bioscienc inc past career mr laranjeira held posit vice president-suppli oper epiru
biopharmaceut inc vp-drug product manufactur latin america bristol-my squibb co senior vice
president-techn oper llc mr laranjeira receiv undergradu degre new
jersey institut technolog
charl reinhart pacira year charl hold posit chief offic pacira bioscienc
inc mr reinhart also board vectorlog inc past mr reinhart occupi posit princip delsi
pharmaceut corp chief offic inc chief offic senior vice presid
pharmathen inc chief offic execut vice presid archimed pharma ltd vice president-fin
cephalon inc princip genvec inc senior vice president-fin strategi takeda oncolog co charl
reinhart receiv undergradu degre lehigh univers wharton school univers
pennsylvania
richard scranton pacira year richard occupi posit chief medic offic pacira
bioscienc inc also assist professor harvard medic school previous chief medic offic
verosci llc receiv doctor east tennesse state univers graduat degre harvard chan
school public health undergradu degre univers tennesse
mcloughlin join pacira chief commerci offic pacira bioscienc inc mr mcloughlin
previous presid remedi group mr mcloughlin receiv undergradu degre st joseph univers
roy winston join pacira founder laseraway llc laseraway medic group inc roy presid chief
execut offic laseraway medic group inc also chief clinic offic inc past
occupi posit chief execut offic laseraway llc dr winston receiv undergradu degre
univers pennsylvania doctor icahn school medicin mount sinai
appendix review exparel efficaci result brachial plexu nerv block
fda approv exparel octob administr surgic site via wound infiltration/field block
produc postsurg analgesia approv base two phase multicent random double-blind placebo-
control studi demonstratr efficaci viscer hemorrhoidectomi nonviscer bunionectomi pain overal
clinic develop program includ clinic studi observ studi initi develop program also
includ phase phase studi evalu exparel nerv block upper/thorac lower extrem
co conduct four phase studi evalu exparel use nerv block brachial pleu inercost femor
nerv block region analgesia studi brachial plexu nerv block summar studi
evalu femor nerv block lower-extrem fda vote addit label
demonstr efficaci region analgesia lower post surgic opioid use fail demonstr durat
block consequ adequ character th safeti profil co current initi anoth phase
studi character safeti profil femor nerv block
studi result patient evalu brachial plexu nerv block tsa/rcr
studi met primari efficaci endpoint patient exparel group show significantli lower cumul
pain intens score auc va hour placebo group
studi also met secondari efficaci endpoint demonstr reduct opioid consumpt mean total opioid
rescu medic use lower exparel vs placebo group significantli patient receiv exparel
use opioid rescu medic compar placebo patient studi demonstr exparel
efficaci region nerv block upper extrem reduc use opioid medic
draft guidanc fda regard bioequival issu feb
co commun fda regard would requir gener version exparel fda issu
follow guidanc would requir gener liposom bupivacain
show fda draft guidanc requir gener co would meet includ clinic studi
gener product qualit quantit refer drug
follow clinic studi recommend demonstr bioequival
type studi fast
subject male nonpregn femal gener popul
addit comment deliv via local subcutan infiltr flank area move needl techniqu use
administr studi treatment period administ least day period treatment
altern sponsor provid non-high-fat diet propos studi treatment initi hour
standard non-high-fat breakfast
analyt measur appropri biolog fluid bupivacain plasma
bioequival base ci bupivacain
waiver request in-vivo test applic
note pivot bioequival studi conduct use test product produc propos commerci scale manufactur
addit inform sponsor
parenter drug product gener bupivacain liposom inject must qualit quantit rld
except differ buffer preserv antioxid provid applic identifi character differ
demonstr differ impact safety/efficaci profil drug product current fda recommend
type studi would need demonstr differ buffer preserv antioxid impact
safety/efficaci profil drug product
lipid excipi critic multivesicular liposom anda sponsor obtain lipid categori synthesi rout
natur synthet found rld formul chemistri manufactur control lipid compon provid
level detail expect drug substanc suggest liposom drug product draft guidanc
local act product complex bioequival requir nasal spray inhal product vitro
liposom character conduct least three batch anda rld product least one anda batch
produc commerci scale process use vivo bioequival studi attribut includ compar
character anda rld product follow
liposom composit lipid content free encapsul drug
intern aqueou environ liposom
liposom particl structur morpholog unlik tradit liposom multivesicular liposom consist non-lamellar
honeycomb structur uniqu structur morpholog import sustained-releas properti structur
morpholog test refer product compar includ intern honeycomb structur
vitro drug releas rate methodolog use vitro drug releas test abl discrimin effect
process variabl product test formul
dissolut test method sampl time applic
heron potenti competitor exparel
heron develop bupivacain meloxicam post-op surgeri indic
pacira fix dose combin local anesthet bupivacain nonsteroid anti-inflammatori drug
nsaid meloxicam low-dos meloxicam reduc inflamm site surgeri
bupivacain act stronger efficaci two dose encapsul proprietari biochronom technolog
extend efficaci hour
heron releas posit top-line phase result epoch studi bunionectomi epoch studi
herniorrhaphi given fast track prioriti review design heron receiv may co refil
nda octob fda accept file assign pdufa goal date march
data rel posit call kol note needle-fre method administr
someth surgeon experi describ viscou glue-lik product comparison
liposom bupivacain similar consist standard care bupivacain
reduc pain intens opioid consumpt versu bupivacain hcl bunionectomi
phase result random epoch studi
total subject dose random double-blind placebo-control active-control phase studi
patient undergo primari unilater distal first metatars bunionectomi subject receiv either singl
intraop dose immediate-releas bupivacain hcl salin placebo
subject receiv show reduct mean pain intens hour compar salin placebo
vs primari endpoint compar bupivacain hcl vs
cours hour total opioid consumpt significantli reduc receiv
compar placebo vs receiv bupivacain hcl
proport subject experienc sever pain time hour
proport subject opioid free hour popul hcl
hydrochlorid intent treat
viscusi et al reduc pain intens opioid consumpt
versu bupivacain hcl herniorrhaphi
viscusi et al reduc pain intens
bioscienc inc statement financi project product licens mileston acquir intang charg loss expens effect rate tax benefit incom averag basic averag dilut
bioscienc inc sheet cash equival receiv expens current current asset invest senior tax current senior equiti prefer stock par valu share author share issu stock par valu share author share issu andoutstand june share issu outstand decemb paid-in comprehens incom liabil stockhold
bioscienc inc statement flow oper activ oper right-of-us dispos fix asset liabil account expens current long-term expens current liabil long-term cash chang
btig cover compani mention report
appendix analyst certif import disclosur
